Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced Inoperable or Metastatic Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative HR+/HER2? Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor CAPItello-291

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04305496

Study #:
STUDY00145332

Start Date:
Sep 07, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04305496

View Complete Trial Details & Eligibility at ClinicalTrials.gov